Evidence map›Paper›PMID 37142890›Full record

ArticleImmunologic research2023

Coexistence of malignancies in pemphigus vulgaris.

Karin Warshavsky, Tal Zeeli, Ori Mekiten, Eli Sprecher, Barbara G Silverman, Aviv Barzilai, Sharon Baum

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Karin WarshavskyDepartment of Dermatology, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.ORCID 0000-0003-0457-2404
Tal ZeeliAffiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Ori MekitenDepartment of Dermatology, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
Eli SprecherAffiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Barbara G SilvermanAffiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Aviv BarzilaiDepartment of Dermatology, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
Sharon BaumDepartment of Dermatology, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel. baumdr@gmail.com.
Tel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pemphigus vulgaris (PV) is a rare autoimmune intraepidermal bullous disease. PV has a major effect on morbidity as well as quality of life. There is sparse literature regarding the association between pemphigus vulgaris (PV) and comorbid malignancies. In this study we aimed to assess the risk of malignancy in a cohort of patients with PV and characterize PV-associated malignancies. Data were collected from two tertiary referral centers between the years 2008 and 2019 and compared with the national cancer registry. Of 164 patients with PV, 19 were diagnosed with malignancy: seven prior to PV diagnosis and 12 after. All cancers, solid and hematological, displayed higher incidences compared to the general population (p <0.001). In conclusion, we demonstrated higher rates of malignancies among patients with PV than in the general population. These observations suggest the need for careful assessment and follow up of patients with PV, given the possibility of associated malignancies.

Indexed as

Autoimmune DiseasesNeoplasmsPemphigusComorbidityHumansQuality of LifeImmune suppressionMalignancyPemphigusTumors

Identifiers

PMID37142890
OpenAlexW4368362758

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.